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CLINICAL SCENARIO
A 68 year old woman presented to the clinic with
dysuria and urinary frequency. Subsequent physi-
cal examinations and laboratory tests revealed a
positive urinary tract infection. She has been
treated for urinary tract infections 3 times in the
past 8 months. The patient asked how to prevent
recurrent episodes of urinary tract infections as it
significantly decreases her quality of life.
INTRODUCTION
Urinary tract infections (UTI) are commonly found
in daily practice. International Urogynecological
Association/International Continence Society (2010)
defined recurrent urinary tract infections as at
least three symptomatic and medically diagnosed
UTI in the previous 12 months. The previous UTIs
should have resolved prior to a further UTI being
diagnosed.1
Abstract
Objective: To determine the most effective and applicable methods
to reduce recurrence of urinary tract infections in postmenopausal
women.
Method: A search was conducted on Pubmed, NEJM, BMJ, and Goo-
gle. After screening and selection, six articles were considered use-
ful; comprising of two original research articles, one systematic re-
view, and three society guidelines.
Result: Society guidelines recommended continuous antimicrobial
prophylaxis, with postcoital antimicrobial prophylaxis as an alter-
native. The first research article found similar results in continous
antimicrobial prophylaxis group and intermittent antimicrobial pro-
phylaxis group. The second research article found no significant dif-
ference in cranberry and trimethoprim group. The systematic re-
view revealed vaginal estrogens are effective in preventing recur-
rent UTI, but the type of estrogen is less clear. Oral estrogens are not
effective.
Conclusion: Prevention of recurrent urinary tract infections in post-
menopausal women include risk factor identification, non-antimi-
crobial prophylaxis with cranberry and vaginal estrogen prepara-
tions, and antimicrobial prophylaxis (continuous or intermittent).
[Indones J Obstet Gynecol 2014; 2-1: 55-60]
Keywords: postmenopausal, prevention, recurrent urinary tract in-
fection.
Abstrak
Tujuan: Mengetahui metode yang paling efektif dan yang paling da-
pat diterapkan untuk mencegah berulangnya infeksi saluran kemih
pada perempuan pascamenopause.
Metode: Pencarian literatur dilakukan di Pubmed, NEJM, BMJ, dan
Google. Setelah dilakukan skrining dan pemilihan literatur, didapat-
kan enam literatur yang sesuai dengan pertanyaan klinis. Literatur
tersebut terdiri dari dua artikel penelitian, satu telaah sistematis, dan
tiga panduan organisasi.
Hasil: Pada panduan organisasi, dianjurkan untuk menggunakan an-
tibiotik profilaksis kontinu sebagai pencegahan ISK berulang, dengan
antibiotik pascakoitus sebagai alternatif. Pada artikel penelitian per-
tama tidak ditemukan perbedaan pada kelompok antibiotik pro-filak-
sis dan intermiten. Pada artikel penelitian kedua tidak ditemukan
perbedaan pada kelompok cranberry dan trimetoprim. Pada telaah
sistematis disimpulkan bahwa sediaan estrogen vagina efektif untuk
mencegah berulangnya ISK. Estrogen oral tidak efektif untuk men-
cegah berulangnya ISK.
Kesimpulan: Pencegahan ISK berulang pada perempuan pascame-
nopause mencakup identifikasi faktor risiko, profilaksis non-antimi-
kroba dengan cranberry dan preparat estrogen vagina, dan profilaksis
antimikroba, baik kontinu maupun intermiten.
[Maj Obstet Ginekol Indones 2014; 2-1: 55-60]
Kata kunci: infeksi saluran kemih berulang, pascamenopause, pen-
cegahan.
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Escherichia coli is the main causative pathogen
involved in recurrent UTIs, accounting for 80% of
infections.2 Even though the pathogen is the same,
risk factors for recurrent UTIs differ in premeno-
pausal and postmenopausal women. In premeno-
pausal women, behaviour risk factors such as fre-
quency of intercourse, use of spermicide, and new
sexual partners may increase colonization of E. coli
in the vagina and periurethral region.3,4 In post-
menopausal women, estrogen loss results in thin-
ning of the vaginal epithelium and decreased
amounts of glycogen. As a result, amount of lacto-
bacilli decreases and there is an increased risk of
colonization with uropathogens. Moreover, associ-
ated pathologies such as incontinence, pelvic floor
prolapse, and urinary retention increase the risk
for recurrent UTI.5
Various studies have reported the use of antimi-
crobials and non-antimicrobials such as estrogen
and cranberry for preventing recurrence of UTI. In
this EBCR we tried to appraise novel studies and
guidelines in order to obtain information that may
be applied to our case.
CLINICAL QUESTION
The question in the scenario is "In post-meno-
pausal women, what are the effective and applica-
ble methods to reduce the recurrence of urinary
tract infections?"
METHODS
Search Strategy
The search was conducted on Pubmed, NEJM, and
BMJ on February 8, 2013, using the search tool
containing the keywords "recurrent urinary tract
infection", "treatment", "prophylaxis", "elderly wo-
men", and "postmenopausal". Another search was
performed on Google to find organizational or so-
ciety guidelines on recurrent urinary tract infec-
tions. Search results were filtered by the engine ac-
cording to the following criteria: articles published
in the past 5 years, female, human species, and
English language. Search strategy, results, and the
inclusion and exclusion criteria are shown in a
flowchart (Figure 1).
Selection
The titles of the filtered results from Pubmed,
NEJM, and BMJ were screened using the inclusion
criteria. There were no same articles from all three
engines. A second screen was conducted by rea-
ding the abstracts, and finally 3 articles were use-
ful. Three society guidelines were found on Google,
from Society of Obstetricians and Gynaecologists of
Canada (SOGC), American College of Obstetricians
and Gynecologists (ACOG), and European Associa-
tion of Urology (EAU). In this report a total of 6
articles were appraised.
Critical Appraisal
Two articles were original researches, one article
was a systematic review, and three articles were
society guidelines. All were appraised according to
the corresponding type of article, comprising of its
validity, importancy, and applicability to the pa-
tient (Table 1-2). The checklists used were ob-
tained from www.bmj.com.
 
Figure 1. Flowchart of Search Strategy.
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Table 1. Critical Appraisal of Original Research Articles and Systematic Review.
Study/Criteria
Zhong et al6
Experiment: intermittent prophylactic antibiotic
Control: continuous prophylactic antibiotic
McMurdo et al7
Experiment: cranberry
Control: trimethoprim
Validity
• Randomisation Yes Yes
• Intention to treat analysis No Yes
• Blinding No Double-blinding
• Equal treatment besides experiment Yes Yes
• Similarity of groups Yes Yes
Importance
• Control event rate (CER) 29.8% 20.6%
• Experimental event rate (EER) 37.3% 36.2%
• Relative risk reduction (RRR) -7.5% (increased risk) -15.6% (increased risk)
• Absolute risk reduction (AAR) -25.2% (increased risk) -75.7% (increased risk)
• Number needed to treat (NNT) -4 (harm) -2 (harm)
Applicability
• Can the results help the patient? Yes Yes
• Potential benefit of therapy Yes Yes
• Patient satisfaction - -
Table 2. Critical Appraisal of Systematic Reviews.
Study/Criteria Perrotta et al
8
Review of benefit of estrogen
Validity
• Review of randomised trials Yes
• Explanation about finding and including all relevant trials Yes
• Assessing validity of individual trials Yes
• Consistency of results ±
• Individual or aggregate data Individual
Importancy
• Relative risk (95%CI) Oral estrogens vs placebo: 1.08 (0.88-1.33)
Vagina estrogens vs placebo: vaginal cream 0.25 (0.13-0.50),
Vaginal ring 0.64 (0.47-0.86)
Vaginal estrogens vs antibiotics: conflicting results
Applicability
• Can the results help the patient? ±
• Potential benefit of therapy Yes
• Patient satisfaction -
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RESULTS
Zhong et al conducted a randomised controlled
study on 83 postmenopausal women, comparing
the effectiveness and safety of patient-initiated sin-
gle-dose versus continuous low-dose antibiotics.
The incidence of urinary tract infections were sig-
nificantly reduced in both groups, from 5.1 to 1.9
episodes/patient per year (p < 0.001) in the inter-
mittent group, and from 4.7 to 1.4 episodes/patient
per year (p < 0.001) in the continuous group. The
difference between both groups were not statisti-
cally significant. The continuous group had signifi-
cantly less patients experiencing 0 or 1 episode/
year than the intermittent group (59.4% vs 35.5%,
p < 0.05), but it was also associated with signifi-
cantly higher adverse effects (92.5% vs 63.6%, p <
0.05).6
McMurdo et al conducted a double-blind, ran-
domised controlled trial with 137 samples. Occu-
rences of UTI in cranberry group and trimetho-
phrim group was 36.2% and 20.6%, respectively.
The differences in this proportion was not statisti-
cally significant (p 0.084). Withdrawal rate was 9%
from the cranberry group and 16% from the tri-
methoprim group (p = 0.205).7
Perrotta et al reviewed the effectiveness of es-
trogens for preventing recurrent UTI in post-
menopausal women. Nine articles were reviewed,
with three main interventions being conducted:
oral estrogens vs placebo, vaginal estrogens vs pla-
cebo, and vaginal estrogens vs antibiotics. There
was no significant difference in the number of
women with UTI in the oral estrogen vs placebo
group (RR 1.08, 95%CI 0.88-1.33). In the vaginal
estrogen group, both intravaginal estrogen cream
(RR 0.25, 95%CI 0.13-0.50) and silicone vaginal
ring (RR 0.64, 95%CI 0.47-0.86) significantly re-
duced the recurrence of UTI. Results in the vaginal
estrogen vs antibiotics group were conflicting, one
study found less UTI in the antibiotic group (RR
1.30, 95% CI 1.01-1.68) while the other study
found less UTI in the estrogen group (RR 0.09, 95%
CI 0.02-0.36).8
SOGC recommended continuous daily antibiotic
prophylaxis to prevent recurrent UTI. Post-coital
prophylaxis may be used as an alternative in
women with recurrent UTI associated with sexual
intercourse to minimize cost and side effects. An-
tibiotics that can be used as prophylaxis are listed
in Table 5. Acute-self treatment should only be re-
stricted to compliant and motivated patients. Vagi-
nal estrogens and cranberry products are also ef-
fective.9
Table 3. Antimicrobial Prophylaxis for Women with Re-
current Urinary Tract Infections.9
Oral regimens Dose
Continuous prophylaxis
• Cotrimoxazole 1 x 240 mg (daily)
• Nitrofurantoin 1 x 50-100 mg (daily)
• Cephalexin 1 x 125-250 mg (daily)
• Ciprofloxacin 1 x 125 mg (daily)
• Norfloxacin 1 x 200 mg (daily)
Post-coital prophylaxis
• Cotrimoxazole 240-480 mg single dose
• Nitrofurantoin 100 mg single dose
• Cephalexin 125-250 mg single dose
• Ciprofloxacin 125 mg single dose
• Ofloxacin 100 mg single dose
• Norfloxacin 200 mg single dose
EAU recommended non-antimicrobial prophy-
laxis such as cranberry as a first line of prevention.
If unsuccessful, continuous or postcoital antimicro-
bial prophylaxis should be considered.10
ACOG recommended to first search for known
risk factors associated with recurrence, such as fre-
quent intercourse, long-term spermicide use, dia-
phragm use, new sexual partner, young age at first
UTI, and maternal history of UTI. Similar to other
guidelines, prophylaxis can be continuous or post-
coital.11
COMMENTARY
In general, all appraised articles showed similar
methods or recommendations to prevent recurrent
UTI.
All three society guidelines satisfied the validity,
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usefulness, and applicability criteria. Recommen-
dations are applicable in daily practice, and all
three guidelines support each other. Continuous or
postcoital antibiotics to prevent recurrent UTI was
recommended in all three guidelines.9-11
Zhong et al conducted a very interesting re-
search concerning antimicrobial prophylaxis, com-
paring continuous or intermittent antibiotic pro-
phylaxis as recommended by all three society
guidelines. Predisposing factors used to determine
when to begin prophylactic single-dose antibiotic
are: working or walking > 2 hours, travelling, emic-
tion holdback, sexual intercourse, diarrhea, and
constipation. The authors concluded that patient-
initiated intermittent antibiotic use against specific
predisposing factors showed similar effectiveness
with continuous antibiotic use, but with less gas-
trointestinal adverse events.6 Nevertheless, results
proved unsignificant statistically may be significant
clinically, so we must consider the risk and benefits
when choosing mode of antimicrobial prophylaxis.
Continuous prophylaxis may be more effective for
preventing recurrence of UTI than intermittent
prophylaxis, but is associated with more side ef-
fects. The weakness in this study is the lack inten-
tion-to-treat analysis, as it may affect the results.
McMurdo et al compared the effectiveness of
cranberry to trimethoprim. It is a well-conducted
study with double-blinding and intention-to-treat
analysis. Results could have been more conclusive
and applicable if they included another group
treated with vaginal estrogens. Cranberry and tri-
methoprim had no significant differences in terms
of reducing UTI and adverse effects.7
Perrotta et al conducted a systematic review to
evaluate the role of estrogens in preventing recur-
rent UTIs. This review is valid and important, but
may not be applied directly as the researches re-
viewed are few small studies. They concluded that
vaginal estrogens are effective, but the type of es-
trogen to use is less clear. Vaginal creams are
cheaper but may be hard to apply for some women
as it has to be applied every day. Vaginal rings are
expensive and requires a trained doctor to place
correctly. Oral estrogens are not effective to pre-
vent recurrent UTIs.8
CONCLUSION AND RECOMMENDATIONS
Prevention of recurrent urinary tract infections in
postmenopausal women include risk factor identi-
fication, non-antimicrobial prophylaxis, and anti-
microbial prophylaxis. Consumption of cranberry
and usage of vaginal estrogens are effective non-
antimicrobial measures. Antimicrobial prophylaxis
are divided into continuous single dose daily pro-
phylaxis and intermittent self-initiated prophyla-
xis. Choice of prophylaxis method depends on the
compliance of the patient, as intermittent self-ini-
tiated prophylaxis require identification and awa-
reness on when to consume the drug.
In Indonesia, there are limitations in the non-an-
timicrobial prophylaxis group. Vaginal estrogens
are expensive and cranberry are hard to obtain.
Therefore, the mode of prevention is suited to the
preference of the patient and availability of drugs
in that area.
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